Meeting
2019 ASCO Annual Meeting
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Authors
Arielle Lutterman Heeke
Levine Cancer Institute, Atrium Health, Charlotte, NC
Arielle Lutterman Heeke , Joanne Xiu , Filipa Lynce , Paula Raffin Pohlmann , Gregory A. Vidal , Claudine Isaacs , Sandra M. Swain , Lee S. Schwartzberg , Antoinette R. Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3132)
DOI
10.1200/JCO.2019.37.15_suppl.3132
Abstract #
3132
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).
First Author: Heidi Chwan Ko
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan